{"id":"NCT01696058","sponsor":"Boehringer Ingelheim","briefTitle":"Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®","officialTitle":"A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-09","primaryCompletion":"2013-10","completion":"2013-10","firstPosted":"2012-09-28","resultsPosted":"2014-11-10","lastUpdate":"2014-11-25"},"enrollment":1137,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Disease, Chronic Obstructive"],"interventions":[{"type":"DRUG","name":"Tiotropium","otherNames":[]},{"type":"DRUG","name":"Placebo matching Olodaterol","otherNames":[]},{"type":"DRUG","name":"Tiotropium","otherNames":[]},{"type":"DRUG","name":"Olodaterol","otherNames":[]}],"arms":[{"label":"Olodaterol andTiotropium","type":"EXPERIMENTAL"},{"label":"Placebo and Tiotropium","type":"OTHER"}],"summary":"The overall objective of this study is to assess efficacy and safety of 12 weeks, once daily, orally inhaled co-administration of olodaterol 5 µg (delivered by the Respimat® Inhaler) and tiotropium (delivered by the Handihaler® as Spiriva Handihaler®), compared to tiotropium (Spiriva Handihaler®) monotherapy on lung function in patients with COPD.","primaryOutcome":{"measure":"FEV1 AUC0-3h Response at 12 Weeks; Defined as Change From Baseline to Week 12","timeFrame":"baseline and 12 weeks","effectByArm":[{"arm":"Olodaterol (5μg) and Tiotropium (18μg)","deltaMin":0.297,"sd":0.01},{"arm":"Placebo and Tiotropium (18μg)","deltaMin":0.191,"sd":0.01}],"pValues":[{"comp":"OG000 vs OG001","p":"<.0001"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":94,"countries":["United States"]},"refs":{"pmids":["25342898"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":24,"n":566},"commonTop":["Chronic obstructive pulmonary disease"]}}